TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15894837
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (temocapril 1 mg + losartan 12.5 mg)
Study: 15894837
Drug: Temocapril 1
Normalized name: temocapril
DrugBank: Temocapril (DB08836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temocapril 1 mg
Study: 8506890
Drug: Standardized garlic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized garlic powder tablets (300 mg three times a day)
Study: 24286115
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart administered by InsuJet
Study: 24286115
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart administered by FlexPen
Study: 18695272
Drug: Oral salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral salbutamol (0.1 mg/kg/dose) three times a day for 7 days
Study: 18695272
Drug: Oral salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral salbutamol (0.1 mg/kg/dose)
Study: 12127929
Drug: Ala‐Gln group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ala‐Gln group received 0.972 g amino acids/kg/day and 0.417 g of L‐alanyl‐L‐glutamine (Ala‐Gln)/kg/day.
Study: 12127929
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Conv) received 1.5 g amino acids/kg/day.
Study: 1697824
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin administration
Study: 668268
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml of aqueous ethanol diluted to 25% administered orally
Study: 30590412
Drug: Dolutegravir (DTG)-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir (DTG)-based therapy
Study: 30590412
Drug: Protease inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor (PI/r)-based therapy
Study: 16709215
Drug: Toremifene 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene 20 mg daily
Study: 11706099
Drug: 9 mg
Normalized name: fiber 469 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg IA r‐proUK over 120 minutes plus IV fixed‐dose heparin
Study: 11706099
Drug: IV fixed‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV fixed‐dose heparin alone
Study: 11706099
Drug: r‐proUK treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐proUK treatment
Study: 9681371
Drug: Pemoline 10
Normalized name: pemoline 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemoline 10 mg
Study: 9681371
Drug: Pemoline 20
Normalized name: pemoline 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemoline 20 mg
Study: 9681371
Drug: Pemoline 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemoline 30 mg
Study: 9681371
Drug: Pemoline 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemoline 40 mg
Study: 2371369
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day haloperidol
Study: 2371369
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day haloperidol
Study: 2371369
Drug: 80 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/day haloperidol
Study: 2553993
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with IFN-beta and IFN-gamma
Study: 1106935
Drug: Digoxin solution
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin solution in capsule form
Study: 1106935
Drug: Digoxin tablets
Normalized name: Digoxin Tablets
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin tablets with 97% dissolution rate
Study: 1106935
Drug: Digoxin formulations
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin formulations
Study: 12194393
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml 2% lidocaine
Study: 27595956
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml 1% lidocaine
Study: 24355668
Drug: Daily self-weighing
Normalized name: DAILY SELF DISCOVERY SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily self-weighing intervention
Study: 22173280
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg alone
Study: 22173280
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg co-administered with gemfibrozil 600 mg
Study: 20848164
Drug: midazolam (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: midazolam (0.04 mg/kg)
Study: 20848164
Drug: droperidol (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: droperidol (0.1 mg/kg)
Study: 17851194
Drug: NICE appraisal
Normalized name: nicergoline
DrugBank: Nicergoline (DB00699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NICE appraisal of cholinesterase inhibitors
Study: 12456899
Drug: EMLA on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMLA on the skin and orally administered placebo (sterile water)
Study: 10525592
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg cisatracurium (3x ED(95))
Study: 10525592
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg cisatracurium (2x ED(95))
Study: 10525592
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg atracurium (2x ED(95))
Study: 10525592
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three groups (0.1 mg/kg cisatracurium, 0.15 mg/kg cisatracurium, 0.5 mg/kg atracurium)
Study: 7018179
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 5 mg orally
Study: 7018179
Drug: Pindolol 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol 1.0 mg i.v.
Study: 7018179
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ISDN and pindolol
Study: 6656169
Drug: 3100 NOON-Units
Normalized name: NOON Cartessa Accelerate Program KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3100 NOON-Units (NU) with 3 injections in group A
Study: 6656169
Drug: 9100 NOON-Units
Normalized name: NOON Cartessa Accelerate Program KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9100 NOON-Units (NU) with 6 injections in group B
Study: 24474647
Drug: 9-beam lasercomb
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-beam lasercomb treatment in female subjects
Study: 24474647
Drug: 12-beam lasercomb
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-beam lasercomb treatment in female subjects
Study: 24474647
Drug: 7-beam lasercomb
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-beam lasercomb treatment in male subjects
Study: 24474647
Drug: 9-beam lasercomb
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-beam lasercomb treatment in male subjects
Study: 24474647
Drug: 12-beam lasercomb
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-beam lasercomb treatment in male subjects
Study: 17484373
Drug: Lactulose 0
Normalized name: lactulose 0.4 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose 0 g (placebo)
Study: 17484373
Drug: Lactulose 2
Normalized name: lactulose 2500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose 2 g (low-dose)
Study: 17484373
Drug: Lactulose 4
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lactulose 4 g (high-dose)
Study: 16286541
Drug: 1 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/kg of IVIG on day 1 and placebo on day 2 (group 1)
Study: 16286541
Drug: 1 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/kg of IVIG on 2 consecutive days (group 2)
Study: 10588559
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL 1% lidocaine with epinephrine 1:200,000
Study: 10588559
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL 1% lidocaine without epinephrine
Study: 8961492
Drug: Morphine via
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine via patient-controlled analgesia system
Study: 1762067
Drug: R-ibuprofen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-ibuprofen (600 mg) plus S-[aromatic-2H4]ibuprofen (10 mg)
Study: 1762067
Drug: S-ibuprofen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-ibuprofen (600 mg)
Study: 1762067
Drug: Racemic ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Racemic ibuprofen (800 mg) plus S-[aromatic-2H4]ibuprofen (10 mg)
Study: 1762067
Drug: Racemic ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Racemic ibuprofen
Study: 1762067
Drug: S-ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-ibuprofen
Study: 7044098
Drug: Cisplatin 120
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 120 mg/m2
Study: 7044098
Drug: Cisplatin 60
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 60 mg/m2
Study: 7044098
Drug: Cisplatin 60
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 60 mg/m2 to 120 mg/m2 crossover
Study: 7044098
Drug: Cisplatin 60
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 60 mg/m2 and 120 mg/m2
Study: 29017158
Drug: n-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 polyunsaturated fatty acids (PUFAs) 2,700 mg/day
Study: 22072466
Drug: Conventional injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional injection technique (CI)
Study: 22072466
Drug: Proximal phalanx
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proximal phalanx injection technique (P1I)
Study: 19336509
Drug: Cholecalciferol (D3)
Normalized name: CHOLECALCIFEROL (D3) 50MCG/DROP
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (D3) - 50,000 IU weekly
Study: 19336509
Drug: Ergocalciferol (D2)
Normalized name: ERGOCALCIFEROL (D2) 200MCG/ML ORAL DROPS
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ergocalciferol (D2) - 50,000 IU weekly
Study: 19336509
Drug: UV light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: UV light therapy - exposed skin to UV light five times a week
Study: 17719312
Drug: Perindopril (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (2 to 4 mg)
Study: 10361264
Drug: Griseofulvin plus
Normalized name: Griseofulvin
DrugBank: Griseofulvin (DB00400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Griseofulvin plus oral prednisolone
Study: 1773708
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin alone
Study: 1773708
Drug: Syringe mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syringe mixed regular and NPH insulin
Study: 7333003
Drug: Inhaled metaproterenol
Normalized name: metaproterenol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled metaproterenol given 10 min before exercise
Study: 7333003
Drug: Inhaled metaproterenol
Normalized name: metaproterenol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled metaproterenol given 1 hr before exercise
Study: 7333003
Drug: Metaproterenol tablets
Normalized name: metaproterenol Oral Tablet
DrugBank: Orciprenaline (DB00816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metaproterenol tablets given 1 hr before exercise
Study: 7333003
Drug: Metaproterenol tablets
Normalized name: metaproterenol Oral Tablet
DrugBank: Orciprenaline (DB00816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metaproterenol tablets given 2 hr before exercise
Study: 31413896
Drug: Botulinum neurotoxin
Normalized name: Botulinum neurotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum neurotoxin type A treatment
Study: 30006297
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D deficiency ([25(OH)D] < 20 ng/ml)
Study: 27858079
Drug: bFGF 35000IU
Normalized name: bFGF
DrugBank: Basic Fibroblast Growth Factor (DB14131)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bFGF 35000IU + normal saline 20 mL, compression inhalation, day 1, every 20min, continued for 3 d
Study: 27858079
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline 5 mL + dexamethasone 5 mg + gentamicin 80000 U + chymotrypsin 4000 U, compression inhalation, twice a day, every 20 min, continued for 3 d
Study: 25070547
Drug: Continuous cycling
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous cycling (CC) using 20 mcg ethinyl estradiol/100 mcg levonorgestrel with no hormone-free interval
Study: 25070547
Drug: Increased dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dose (ID) using 30 mcg ethinyl estradiol/150 mcg levonorgestrel cyclically
Study: 18490196
Drug: CSE 900
Normalized name: PHOSPHORIC ACID 1500 mg in 10 L / BENZALKONIUM CHLORIDE 400 mg in 10 L / N-ALKYL ETHYLBENZYL DIMETHYL AMMONIUM CHLORIDE (C12-C14) 400 mg in 10 L TOPICAL LIQUID [StepSept CSE-200]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSE 900 mg
Study: 15666173
Drug: Milk thistle
Normalized name: MILK THISTLE
DrugBank: Milk thistle (DB14375)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk thistle (450 mg extract capsules t.i.d. from day 2 to day 30)
Study: 1625204
Drug: Bromocriptine (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (0, 1.2 and 2.5 mg given orally 2 hr before the cocaine injection)
Study: 26940371
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three test solutions
Study: 20620265
Drug: Monotherapy or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy or combination therapy for manic/mixed episodes
Study: 20620265
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics (monotherapy or in combination)
Study: 17936411
Drug: Adalimumab (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (40 mg) every other week for the first 15 weeks
Study: 17936411
Drug: Adalimumab (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (continuous treatment)
Study: 9005787
Drug: Ofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (200 mg intravenously twice a day for 3 days, then orally at the same dosage)
Study: 3087678
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (22.5 cm2 mean dose)
Study: 30953306
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of opt-out testing and financial incentives
Study: 22127938
Drug: Reinforced feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinforced feedback in virtual environment (RFVE) therapy
Study: 22127938
Drug: RFVE therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: RFVE therapy in haemorrhagic group
Study: 22127938
Drug: TNR therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNR therapy in haemorrhagic group
Study: 22127938
Drug: RFVE therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: RFVE therapy in ischaemic group
Study: 22127938
Drug: TNR therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNR therapy in ischaemic group
Study: 19359142
Drug: Combination message
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination message (high fiber/low saturated fat)
Study: 16903985
Drug: r-hGH 4
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-hGH 4 mg daily (group A)
Study: 16903985
Drug: Drug-related side
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-related side effects in group A
Study: 16903985
Drug: Drug-related side
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-related side effects in group B
Study: 11743379
Drug: Amrinone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amrinone (5 mg/ml)
Study: 10975630
Drug: Alcohol (0.62
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.62 g/kg)
Study: 2500472
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy without acute cardiac catheterization
Study: 19260631
Drug: Postoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative treatment with hemisuccinate of hydrocortisone or dexamethasone
Study: 19260631
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy without cortisone
Study: 16444031
Drug: Prestarium (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prestarium (an angiotensin-converting enzyme inhibitor)
Study: 10475140
Drug: Tilidine/Naloxone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilidine/Naloxone (50 mg/4 mg)
Study: 10475140
Drug: Bromfenac (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromfenac (75 mg)
Study: 10475140
Drug: Bromfenac (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromfenac (25 mg)
Study: 10475140
Drug: Bromfenac (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromfenac (50 mg)
Study: 2143687
Drug: MCV +
Normalized name: Methylcellulose
DrugBank: Methylcellulose (DB11228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCV + CYP 300 mg/m2
Study: 2143687
Drug: MCV +
Normalized name: Methylcellulose
DrugBank: Methylcellulose (DB11228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCV + CYP 150 mg/m2
Study: 2143687
Drug: MCV +
Normalized name: Methylcellulose
DrugBank: Methylcellulose (DB11228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCV + CYP 75 mg/m2
Study: 322242
Drug: Floctafenine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Floctafenine (200 mg)
Study: 26400023
Drug: Decitabine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decitabine (15 mg/m² every 8 h for 3 days)
Study: 21546216
Drug: Artemisinin 100mg
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin 100mg twice a day for 10 weeks
Study: 18439596
Drug: recombinant follicle-stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant follicle-stimulating hormone (FSH)
Study: 17481615
Drug: 750-mug tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750-mug tablets (2 tablets of 0.75 mg each)
Study: 15621576
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) treatment
Study: 11677390
Drug: All five
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All five techniques administered to another 19 participants
Study: 9840526
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (cisplatin 60 mg/m2 and epirubicin 110 mg/m2 on Day 1 for 2-3 cycles) followed by radiotherapy (66-74 Gy to primary tumor, median 71 Gy; 60-76 Gy to neck, median 66 Gy)
Study: 9840526
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (cisplatin and epirubicin) followed by radiotherapy
Study: 3186777
Drug: Sunflower seed
Normalized name: SUNFLOWER SEED
DrugBank: Sunflower seed (DB10907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower seed and linseed oil capsules
Study: 86666
Drug: Oral antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antimicrobial prophylaxis (metronidazole and kanamycin)
Study: 28435054
Drug: Palucorcel (human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palucorcel (human umbilical tissue-derived cells) administered in 33 eyes
Study: 20227549
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of mifepristone followed 48 h later by 400 mcg oral misoprostol (Group 1)
Study: 20227549
Drug: 800‐mcg intravaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800‐mcg intravaginal single‐dose misoprostol (Group 2)
Study: 15656879
Drug: warfarin 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: warfarin 1.25 mg plus aspirin 75 mg daily
Study: 15656879
Drug: aspirin 75
Normalized name: aspirin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin 75 mg alone
Study: 11893234
Drug: Paroxetine 10
Normalized name: PARoxetine 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 10 to 50 mg/day
Study: 11893234
Drug: Paroxetine 10
Normalized name: PARoxetine 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 10 to 40 mg/day
Study: 11893234
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 to 60 mg/day
Study: 10373134
Drug: Inhaled formoterol
Normalized name: formoterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled formoterol (12 microg twice a day)
Study: 2230910
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g mezlocillin and 200 mg netilmicin as an i.v. bolus before implantation
Study: 2230910
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g mezlocillin before and then 6 and 12 hours after surgery and 200 mg netilmicin before and then 12 hours after implantation
Study: 26002111
Drug: Primary chemotherapy
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary chemotherapy (3 cycles followed by surgery and then 3 cycles of completion chemotherapy)